Failure of anakinra in a CASE of severe Hidradenitis suppurativa

Journal of Drugs in Dermatology

Volumn 15, Issue 6, 2016, Pages 772-774

  Russo, Veronica ^a   Alikhan, Ali ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; C REACTIVE PROTEIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD CELL COUNT; BUTTOCK; CASE REPORT; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HUMAN; LEUKOCYTOSIS; MALE; MIDDLE AGED; MONOTHERAPY; ONCOLOGIST; SUPPURATIVE HIDRADENITIS; TREATMENT DURATION; TUBERCULIN TEST; DRUG ADMINISTRATION; HIDRADENITIS SUPPURATIVA; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE;

DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HIDRADENITIS SUPPURATIVA; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 84994415755     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60:539-61.
2. Alavi A, Anooshirvani N, Kim WB, et al. Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study. Am J Clin Dermatol. 2015;16:61-5.
3. Esmann S and Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91:328-32.
4. Rambhatla PV, Lim HW, and Hamzavi I. A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol. 2012;148:439-46.
5. Leslie KS, Tripathi SV, Nguyen TV, et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70:243-51.
6. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: What do Dermatology Life Quality Index Scores mean? J Invest Dermatol. 2005;125:659-64.
7. van der Zee HH and Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes. J Am Acad Dermatol. 2015;73:S23-6.
8. Zarchi K, Dufour DN, and Jemec GB. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 2013;149:1192-4.
9. Tzanetakou V, Kanni T, and Giatrakou S. Safety and efficacy of anakinra in severe hidradenitis suppurativa: A randomized clinical trial. JAMA Dermatol. 2015;18:1-9.
10. Menis D, Maroñas-Jiménez L, Delgado-Marquez AM, et al. Two cases of severe hidradenitis suppurativa with failure of anakinra therapy. Br J Dermatol. 2015;172:810-1.
11. van der Zee HH and Prens EP. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology. 2013;226:97-100.
12. Mertens M, Singh JA. Anakinra for rheumatoidarthritis: a systematic review. J Rheumatol. 2009;36:1118-1125.